Rectovaginal fistula during treatment with axitinib in a patient with renal cell carcinoma: a case report and review of the literature.

abstract：:We chose to treat malignant pleural mesothelioma with a combination of docetaxel and irinotecan (CPT-11), because there have been preliminary reports that CPT-11 is active against mesothelioma, and docetaxel and CPT-11 were the most active agents in our in vitro experiments in human mesothelioma cell lines. Fifteen pr...

journal_title：Anti-cancer drugs

authors： Knuuttila A,Ollikainen T,Halme M,Mali P,Kivisaari L,Linnainmaa K,Jekunen A,Mattson K

更新日期：2000-04-01 00:00:00

abstract：:Aberrant expression of the epidermal growth factor receptor (EGFR) system has been reported in a wide range of epithelial cancers. In some studies, this has also been associated with a poor prognosis and resistance to the conventional forms of therapies. These discoveries have led to the strategic development of sever...

journal_title：Anti-cancer drugs

authors： Modjtahedi H,Essapen S

更新日期：2009-11-01 00:00:00

abstract：:A phase II trial was performed to determine the efficacy and tolerance of docetaxel plus oxaliplatin with hematopoietic growth factor support in previously untreated patients with advanced gastroesophageal adenocarcinoma. Thirty-five patients were entered in this trial. Treatment consisted of 3-weekly docetaxel 80 mg/...

journal_title：Anti-cancer drugs

authors： Hejna M,Raderer M,Zacherl J,Ba-Ssalamah A,Püspök A,Schmidinger M,Pluschnig U,Brodowicz T,Zielinski CC

更新日期：2008-06-01 00:00:00

abstract：:In this study the activity of KW-2149 and two of its metabolites, M-16 and M-18, was measured against cell lines with different types of resistance. The influence of these metabolites and of the exposure time on the cytotoxic efficacy of KW-2149 was investigated. Against the human ovarian carcinoma cell lines, AOvC an...

journal_title：Anti-cancer drugs

authors： Dirix LY,Gheuens EE,van der Heyden S,van Oosterom AT,De Bruijn EA

更新日期：1994-06-01 00:00:00

abstract：:The aim of this phase II study was to evaluate safety and efficacy of an oxaliplatin/vinorelbine/5-fluorouracil (FON) combination in anthracycline and taxane-pretreated metastatic breast cancer patients. The following treatment was given: on day 1 of a 21-day cycle, oxaliplatin 130 mg/m (2-h intravenous infusion); on ...

journal_title：Anti-cancer drugs

authors： Delozier T,Guastalla JP,Yovine A,Levy C,Chollet P,Mousseau M,Delva R,Coeffic D,Vannetzel JM,Zazzi ES,Brienza S,Cvitkovic E

更新日期：2006-10-01 00:00:00

abstract：:Combretastatin A4 phosphate (CA4P) is a prodrug that selectively destroys tumor blood vessels, and has shown efficacy as a targeted anticancer drug in both animal models and clinical trials. The aims of this single-center, open label, phase I clinical trial were to investigate the safety and tolerability of CA4P admin...

journal_title：Anti-cancer drugs

authors： Liu P,Qin Y,Wu L,Yang S,Li N,Wang H,Xu H,Sun K,Zhang S,Han X,Sun Y,Shi Y

更新日期：2014-04-01 00:00:00

abstract：:The objective of this study was to determine the safety and efficacy of intravesical novantrone in refractory superficial bladder cancer. The eligibility criteria included proven carcinoma in situ or superficial transitional cell carcinoma of the bladder at stage Ta or T1 that was proven refractory to or in relapse af...

journal_title：Anti-cancer drugs

authors： Sharifi R,Lee M,Clayton M,Lamb D,Siami P,Strub M,Albert D,Sarosdy M

更新日期：1991-04-01 00:00:00

abstract：:The clinical development of combinations of cisplatin or carboplatin with DNA topoisomerase I (Topo I) inhibitors is based on their overlapping spectrum of antitumor activity and their in vitro synergy, but is limited by significant hematotoxicity. We studied the cellular interactions between oxaliplatin and topotecan...

journal_title：Anti-cancer drugs

authors： Goldwasser F,Bozec L,Zeghari-Squalli N,Misset JL

更新日期：1999-02-01 00:00:00

abstract：:We evaluated economic implications of treatment with irinotecan, following a RCT which demonstrated significantly increased survival at 1 year with irinotecan (45%) compared to infusional 5-fluorouracil (5-FU) (32%) in patients with metastatic colorectal cancer. Medical care consumption data were collected prospective...

journal_title：Anti-cancer drugs

authors： Schmitt C,Blijham G,Jolain B,Rougier P,Van Cutsem E

更新日期：1999-07-01 00:00:00

abstract：:Over the past decade a number of vascular complications have emerged, such as newly developed or worsened hypertension, in patients who were administered with new cancer treatments for several types of cancer that were untreatable earlier. Hypertension is emerging as one of the most common adverse effects of therapy w...

journal_title：Anti-cancer drugs

authors： Aparicio-Gallego G,Afonso-Afonso FJ,León-Mateos L,Fírvida-Pérez JL,Vázquez-Estévez S,Lázaro-Quintela M,Ramos-Vázquez M,Fernández-Calvo O,Campos-Balea B,Antón-Aparicio LM

更新日期：2011-01-01 00:00:00

abstract：:Cryptophycin (CP)-52, a synthetic analog of CP-1, possesses potent and selective antiproliferative activity against human solid tumors both and. Based on an algorithm developed in this laboratory using HCT-116 human colon adenocarcinoma cells, CP-52 exhibited a time- and concentration-dependent antiproliferative effec...

journal_title：Anti-cancer drugs

authors： Subramanian B,Nakeff A,Media JE,Wiegand RA,Valeriote FA

更新日期：2002-11-01 00:00:00

abstract：:Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, originally developed for lowering cholesterol. Statins also have pleiotropic effects, independent of cholesterol-lowering effects, including induction of apoptosis in various cell lines. However, the mechanism underlying statin-induced apoptosi...

journal_title：Anti-cancer drugs

authors： Zhang S,Wang XL,Gan YH,Li SL

更新日期：2010-08-01 00:00:00

abstract：:A lack of cross-resistance between the aromatase inhibitors (AIs) provides evidence to suggest that there are clinical differences between these agents. Available data from clinical trials indicate that patients exposed to nonsteroidal AIs may benefit from a steroidal compound of similar biochemical potency, and durab...

journal_title：Anti-cancer drugs

authors： Lønning PE

更新日期：2008-03-01 00:00:00

abstract：UNLABELLED:Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 micrograms/kg/day). Median (range) age was 49 (29-81) years and performa...

journal_title：Anti-cancer drugs

authors： Kudelka AP,Winn R,Edwards CL,Downey G,Greenberg H,Dakhil SR,Freedman RS,LoCoco S,Umbreit J,Delmore JE,Arbuck S,Loyer E,Gacrama P,Fueger R,Kavanagh JJ

更新日期：1997-08-01 00:00:00

abstract：:Weekly and triweekly cisplatin-alone concomitant chemoradiotherapy regimens after radical surgery were compared in stages IB-IIA cervical cancer with intermediate- or high-risk factors to identify the better therapeutic regimen. We retrospectively analyzed patients with stages IB-IIA cervical cancer who received radic...

journal_title：Anti-cancer drugs

authors： Zhu J,Lou R,Ji S,Wu G,Chen Q,Hu Q,Zhao Y,Cai D,Gu K

更新日期：2021-02-01 00:00:00

abstract：:Compounds that could block tumor angiogenesis and induce tumor cell differentiation in malignant gliomas represent a very valuable tool in anticancer treatments. In this paper, we demonstrate that more selective drugs, which interfere with specific cellular targets, could treat glioma more effectively. 8-Cl-cAMP and t...

journal_title：Anti-cancer drugs

authors： Drabek K,Pesić M,Piperski V,Ruzdijić S,Medić-Mijacević L,Pietrzkowski Z,Rakić L

更新日期：2000-10-01 00:00:00

abstract：:Four novel 4-substituted 5-nitrophthalimides (5-substituted-6-nitro-1,3-dihydro-isoindol-1,3-diones), 6, 7, 10 and 11, and the known 5 are prepared as analogs of the dinitrobenzamide prodrug CB 1954, 1, and considered as potential candidates for gene-directed enzyme prodrug therapy. All the phthalimides are poor subst...

journal_title：Anti-cancer drugs

authors： Mehta LK,Hobbs S,Chen S,Knox RJ,Parrick J

更新日期：1999-09-01 00:00:00

abstract：:Our objective was to determine the maximum tolerated dose (MTD) of paclitaxel when given as a 7 day continuous i.v. infusion, repeated every 3 weeks, and to evaluate the toxicity and the efficacy of such a schedule of administration as a salvage treatment in ovarian cancer patients pretreated and refractory to 3 or 24...

journal_title：Anti-cancer drugs

authors： Soulié P,Trandafir L,Taamma A,Lokiec F,Brain E,Delord JP,Mita A,Vannetzel JM,Cvitkovic E,Misset JL

更新日期：1997-09-01 00:00:00

abstract：:The goal of our study was to determine whether an apoptosis assay used after short-term drug exposure could predict selective toxicity to cancer cells. To this end we compared the effect of eight anticancer drugs and 10 toxic compounds without known antitumor activity in cultures of human breast cancer cells and norma...

journal_title：Anti-cancer drugs

authors： Frankfurt OS,Krishan A

更新日期：2003-08-01 00:00:00

abstract：:Triterpenoids are structurally diverse organic compounds, characterized by a basic backbone modified in multiple ways, allowing the formation of more than 20 000 naturally occurring triterpenoid varieties. Several triterpenoids, including ursolic and oleanolic acid, betulinic acid, celastrol, pristimerin, lupeol, and ...

journal_title：Anti-cancer drugs

authors： Petronelli A,Pannitteri G,Testa U

更新日期：2009-11-01 00:00:00

abstract：:The cytotoxic activity of bendamustine hydrochloride was evaluated against human ovarian and breast carcinoma cell lines including cell lines resistant to cisplatin and doxorubicin in vitro. The relative degree of resistance to bendamustine hydrochloride was lower in all cell lines compared with cyclophosphamide, melp...

journal_title：Anti-cancer drugs

authors： Strumberg D,Harstrick A,Doll K,Hoffmann B,Seeber S

更新日期：1996-06-01 00:00:00

abstract：:Apalutamide (ARN-509) is an antiandrogen that binds selectively to androgen receptors (AR) and does not show antagonist-to-agonist switch like bicalutamide. We compared the activity of ARN versus bicalutamide on prostate cancer cell lines. The 22Rv1, PC3, and DU145 cell lines were used to study the effect of ARN and b...

journal_title：Anti-cancer drugs

authors： Koukourakis MI,Kakouratos C,Kalamida D,Mitrakas A,Pouliliou S,Xanthopoulou E,Papadopoulou E,Fasoulaki V,Giatromanolaki A

更新日期：2018-04-01 00:00:00

abstract：:We examined the effects of flavone and two polyhydroxylated plant flavonoids (quercetin and fisetin), either singly or in combination with ascorbic acid, on the growth of a human squamous cell carcinoma cell line (HTB 43) in vitro. Fisetin and quercetin significantly impaired cell growth in the presence of ascorbic ac...

journal_title：Anti-cancer drugs

authors： Kandaswami C,Perkins E,Soloniuk DS,Drzewiecki G,Middleton E Jr

更新日期：1993-02-01 00:00:00

abstract：:Four newly synthesized antitumor steroidal compounds were compared, on a molar basis, regarding their ability to induce sister chromatid exchanges (SCEs) and cell division delays. The concept of designing and developing these compounds (1-4) is to enhance the anticancer activity of esteric steroidal derivatives of nit...

journal_title：Anti-cancer drugs

authors： Karayianni V,Papageorgiou A,Mioglou E,Iakovidou Z,Mourelatos D,Fousteris M,Koutsourea A,Arsenou E,Nikolaropoulos S

更新日期：2002-07-01 00:00:00

abstract：:Verapamil, cyclosporin A (CsA), the cyclosporin derivative SDZ PSC 833 and the novel cyclopeptolide SDZ 280-446 were tested for their capacity to chemosensitize a P-glycoprotein (Pgp)-expressing multi-drug resistant (MDR) variant of the CEM human T lymphoblastoid cell subline (CCRF ACTD 400+). That MDR-CEM cell sublin...

journal_title：Anti-cancer drugs

authors： Jachez B,Loor F

更新日期：1993-12-01 00:00:00

abstract：:To compare the mechanical and chemical properties of three commercially available microspheres loaded with irinotecan. LifePearl (200 µm), DC Bead (100-300 µm), and Tandem (100 µm) microspheres were loaded with irinotecan. For loading, elution, and stability determinations, irinotecan concentrations were quantified us...

journal_title：Anti-cancer drugs

authors： Pereira PL,Plotkin S,Yu R,Sutter A,Wu Y,Sommer CM,Cruise GM

更新日期：2016-10-01 00:00:00

abstract：:Tumor-to-tumor metastasis is a rare phenomenon, with around 150 cases being reported in the literature. Breast cancer is the second most commonly reported donor tumor after lung cancer, but thymic epithelial tumors have never been reported as recipient tumors. Furthermore, the thymus is rarely affected by metastases. ...

journal_title：Anti-cancer drugs

authors： Moretto R,Cella CA,Raimondo L,Formisano L,Nappi L,Rescigno P,Buonerba C,Calabrese F,Ottaviano M,Di Lorenzo G,Matano E,Damiano V,Palmieri G

更新日期：2013-08-01 00:00:00

abstract：:Aurora-B kinase overexpression plays important roles in the malignant progression of prostate cancer (PCa). AZD1152-HQPA, as an inhibitor of Aurora-B, has recently emerged as a promising agent for cancer treatment. In this study, we aimed to investigate the effects of AZD1152-HQPA on reactive oxygen species (ROS) gene...

journal_title：Anti-cancer drugs

authors： Zekri A,Mesbahi Y,Ghanizadeh-Vesali S,Alimoghaddam K,Ghavamzadeh A,Ghaffari SH

更新日期：2017-09-01 00:00:00

abstract：:The tetracycline family includes tetracycline, doxycycline and minocycline, all of which have been used as antibiotics effectively for decades. New uses emerged for these compounds after their effect on mitochondrial function was discovered. Cytostatic and cytotoxic activity of these compounds was shown against cell l...

journal_title：Anti-cancer drugs

authors： Saikali Z,Singh G

更新日期：2003-11-01 00:00:00

abstract：:In melanoma, the RAS/RAF/MEK/ERK pathway is frequently activated by mutations in BRAF and NRAS. Selumetinib (AZD6244) is an oral, selective, non-ATP-competitive inhibitor of MEK1/2. Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation. She is currently being treated with selumetin...

journal_title：Anti-cancer drugs

authors： Boers-Sonderen MJ,Desar IM,Blokx W,Timmer-Bonte JN,van Herpen CM

更新日期：2012-08-01 00:00:00